Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Status:
Completed
Trial end date:
2019-12-10
Target enrollment:
Participant gender:
Summary
This is a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group
study of ADS-5102 (amantadine extended release [ER] capsules) in MS patients with walking
impairment. ADS-5102 will be administered once daily at bed time.